TransMedics to Present at Upcoming March Investor Conferences

Rhea-AI Summary

TransMedics (Nasdaq: TMDX) management will present at two investor conferences in March 2026: a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 1:50 p.m. EST, and a virtual presentation at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16, 2026 at 10:00 a.m. EST.

A live and archived webcast and the company's standard investor presentation will be available on the Investors section of the TransMedics website.

Key Figures

TD Cowen conference number: 46th Annual Oppenheimer conference number: 36th Annual TD Cowen date: March 2, 2026 +4 more

7 metrics

TD Cowen conference number 46th Annual TD Cowen 46th Annual Health Care Conference

Oppenheimer conference number 36th Annual Oppenheimer 36th Annual Healthcare MedTech & Services Conference

TD Cowen date March 2, 2026 TD Cowen 46th Annual Health Care Conference date

TD Cowen time 1:50 p.m. EST Scheduled fireside chat time at TD Cowen conference

Oppenheimer date March 16, 2026 Oppenheimer 36th Annual Healthcare MedTech & Services Conference date

Oppenheimer time 10:00 a.m. EST Scheduled virtual presentation time at Oppenheimer conference

Number of conferences 2 Total investor conferences mentioned in the release

Market Reality Check

Price: $133.82 Vol: Volume 434,970 is light a...

low vol

$133.82 Last Close

Volume Volume 434,970 is light at about 0.6x the 20-day average. low

Technical Price $129.84 is modestly above the $123.82 200-day MA and about 16.8% below the $156 52-week high.

Peers on Argus

TMDX gained 1.03% while only one tracked peer (GKOS) appeared in momentum scans,...

1 Down

TMDX gained 1.03% while only one tracked peer (GKOS) appeared in momentum scans, moving ~5.24% down. With mixed moves across close peers, the setup points to stock-specific dynamics rather than a broad sector move.

Historical Context

5 past events · Latest: Feb 10 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 10	Earnings timing	Neutral	-4.3%	Announcement of date and time for Q4 and full-year 2025 results.
Feb 09	Regulatory approval	Positive	+0.9%	Full and unconditional FDA IDE approval for ENHANCE Heart trial.
Jan 12	HQ expansion	Positive	-1.8%	New global headquarters lease and campus expansion in Somerville.
Dec 30	Conference appearance	Neutral	-0.2%	Planned presentation at the 44th Annual J.P. Morgan Healthcare Conference.
Dec 24	Equity grants	Neutral	-2.2%	Inducement stock options and RSUs granted to five new employees.

Pattern Detected

Recent stock reactions to operational and corporate updates have been mixed, with positive regulatory news aligning with gains while expansion news drew a negative reaction.

Recent Company History

Over the last few months, TransMedics announced multiple corporate and regulatory milestones. On Feb 9, 2026, it received full FDA IDE approval for the ENHANCE Heart trial, and the stock rose 0.95%. A January announcement on a new Somerville headquarters and campus drew a -1.76% reaction, suggesting some sensitivity to long-term investment news. Earlier, a J.P. Morgan conference appearance and inducement equity grants in Dec 2025 saw small negative moves. The current investor-conference notice is similar in type to prior event-participation updates.

Market Pulse Summary

This announcement highlights TransMedics’ upcoming visibility at two March investor conferences, wit...

Analysis

This announcement highlights TransMedics’ upcoming visibility at two March investor conferences, with sessions on March 2, 2026 and March 16, 2026. It follows recent regulatory milestones and expansion plans, which previously produced mixed share-price reactions. Investors may focus on any updated commentary shared in these webcasts versus prior disclosures, alongside the forthcoming earnings report and ongoing execution of growth and clinical trial initiatives.

AI-generated analysis. Not financial advice.

ANDOVER, Mass., Feb. 17, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the TD Cowen 46^th Annual Health Care Conference in Boston on Monday, March 2, 2026, at 1:50 p.m. EST and virtually at the Oppenheimer 36^th Annual Healthcare MedTech & Services Conference on Monday, March 16, 2026, at 10:00 a.m. EST.

Event: TD Cowen 46^th Annual Health Care Conference
Date: Monday, March 2, 2026
Time: 1:50 p.m. EST

Event: Oppenheimer 36^th Annual Healthcare MedTech & Services Conference
Date: Monday, March 16, 2026
Time: 10:00 a.m. EST

A live and archived webcast of the presentations will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/. The Company's standard investor presentation is also available through this link.

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
Laine Morgan
332-895-3222
Investors@transmedics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-present-at-upcoming-march-investor-conferences-302689917.html

SOURCE TransMedics Group, Inc.

FAQ

When will TransMedics (TMDX) present at the TD Cowen conference and how can I watch it?

TransMedics will present at TD Cowen on March 2, 2026 at 1:50 p.m. EST. According to the company, a live and archived webcast will be available on the Investors section of the TransMedics website, where the standard investor presentation is also posted.

What time is TransMedics (TMDX) scheduled to speak at the Oppenheimer Healthcare MedTech conference?

TransMedics is scheduled to present virtually at Oppenheimer on March 16, 2026 at 10:00 a.m. EST. According to the company, the session will be webcast live and archived on the Investors section of the TransMedics website.

Will TransMedics (TMDX) provide a replay of the March 2026 investor presentations?

Yes, TransMedics will provide an archived replay of both presentations. According to the company, the live and archived webcasts will be posted on the Investors section of the TransMedics website after each event.

What topics will TransMedics (TMDX) management cover in the March 2026 fireside chat?

The company announced management will participate in a fireside chat but did not list specific topics. According to the company, the session will follow the TD Cowen conference format and the investor presentation is available online.

Where can investors find TransMedics (TMDX) presentation materials for March 2026 events?

Investors can access presentation materials on the company's Investors website. According to the company, the standard investor presentation and live/archived webcasts for both March events are available at investors.transmedics.com.

Are TransMedics (TMDX) presentations in March 2026 in-person or virtual?

The TD Cowen fireside chat is in-person in Boston; the Oppenheimer presentation is virtual. According to the company, the TD Cowen session is March 2, 2026 at 1:50 p.m. EST and Oppenheimer is March 16, 2026 at 10:00 a.m. EST.